Vascular Therapies

Vascular Therapies is a biotechnology company founded in 2001, headquartered in the United States, and focused on enhancing patient outcomes by addressing surgical stenosis in patients with kidney and vascular disease. The company's flagship product is Sirogen™, an investigational sirolimus formulation designed for local, perivascular drug delivery. This innovative product is currently undergoing clinical trials to assess its safety and efficacy in improving vascular access outcomes for patients requiring an arteriovenous fistula for hemodialysis. The company's recent milestone includes securing a $23.96M Venture Round investment on 04 March 2022. This signifies confidence from investors in Vascular Therapies' mission and potential. As the company operates within the health care and pharmaceutical sectors, there is significant potential for the technology to make a substantial impact on patient care and treatment methodologies. Vascular Therapies has the potential to disrupt the treatment landscape for patients with kidney and vascular disease, and the recent investment injection is a strong indicator of investor support. As the company continues to progress through clinical trials and development, all eyes will be on how Sirogen™ could potentially transform the standard of care for these patient populations.